Predicting Hospital Rates of Fluoroquinolone-Resistant Pseudomonas aeruginosa from Fluoroquinolone Use in US Hospitals and Their Surrounding Communities
Open Access
- 15 August 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (4) , 497-503
- https://doi.org/10.1086/422647
Abstract
Rates of fluoroquinolone resistance among Pseudomonas aeruginosa in hospitals are increasing, but interhospital variability is great. We sought to determine whether this variability correlated to fluoroquinolone use in hospitals and in the surrounding community. Hospital quinolone use in 1999 (24 hospitals) through 2001 (35 hospitals) was determined from billing records. The number of fluoroquinolone prescriptions within a 10-mile (∼16-km) radius of each hospital was determined for 1999 and 2000. Hospital fluoroquinolone use increased from 1999 through 2001, from 137 to 163 defined daily doses (DDD)/1000 patient-days (P = .01). The rate of community fluoroquinolone use also increased, from 2.3 to 2.8 DDD/1000 inhabitant-days (P < .001). Rates of fluoroquinolone-resistant P. aeruginosa increased from 29% in 1999 to 36% in 2001 (P = .003). Both community and hospital fluoroquinolone use were predictive of rates of fluoroquinolone-resistant P. aeruginosa. Levofloxacin was associated with resistance, but ciprofloxacin was not. Most of the variability in resistance rates is explained by volume of fluoroquinolone use, both in the hospital and the surrounding community.Keywords
This publication has 29 references indexed in Scilit:
- Relationship between Fluoroquinolone Use and Changes in Susceptibility to Fluoroquinolones of Selected Pathogens in 10 United States Teaching Hospitals, 1991-2000Clinical Infectious Diseases, 2003
- Antimicrobial-Drug Prescription in Ambulatory Care Settings, United States, 1992–2000Emerging Infectious Diseases, 2003
- Antibiotic Resistance Among Gram-Negative Bacilli in US Intensive Care UnitsJAMA, 2003
- Maintaining Fluoroquinolone Class Efficacy: Review of Influencing FactorsEmerging Infectious Diseases, 2003
- Widespread Use of Fluoroquinolones Versus Emerging Resistance in PneumococciClinical Infectious Diseases, 2002
- Ciprofloxacin plus Piperacillin Compared with Tobramycin plus Piperacillin as Empirical Therapy in Febrile Neutropenic PatientsAnnals of Internal Medicine, 2002
- Temporal Changes in Prevalence of Antimicrobial Resistance in 23 U.S. HospitalsEmerging Infectious Diseases, 2002
- Resistance to Levofloxacin and Failure of Treatment of Pneumococcal PneumoniaNew England Journal of Medicine, 2002
- Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?Clinical Infectious Diseases, 2002
- Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in CanadaNew England Journal of Medicine, 1999